However, the incidence and prevalence of IBD has increased rapidly over the last two to four decades. These changes may correlate to the life changes in Asia close to the Western country. We will see the characteristic of our IBD patients from colonoscopy findings. Methods: Descriptive study to describe Inflammatory Bowel Disease (IBD) patients characterized who underwent colonoscopy at Cipto Mangunkusumo

Hospital (RSCM) from 2009 until 2013. We had 2,234 patients who underwent colonoscopy from January 2009 until December 2013. Results: From colonoscopy PLX4032 in vitro patients, there were normal colonoscopy 14.2%, hemorrhoid 66.3%, tumor 20.5%, polyp 13.2%, IBD 9.8%, infective colitis 6.2% and ileitis 5.7%.The incidence of IBD 9.8% (219 cases of IBD from 2,234). The ulcerative colitis

(UC) was 192 cases (87.7%) which male gender 44.8%, female 55.2%, and average age 47.8 ± 15.75 years. Crohn’s Disease (CD) was 27 cases (12.3%) which male gender 40.7%, female 59.3%, and average age 40.96 ± 16.24 years. There are significant difference for average age between UC and CD (47.81 ± 15.75 vs 40.96 ± 16.25, RXDX-106 cost p = 0.04). Most of the clinical symptoms are chronic diarrhea 78.6%, then abdominal pain 55%, hematochezia 46.8%, abdominal mass 5% and constipation 5%. Chronic diarrhea was the most of clinical symptoms for UC and CD. Conclusion: The incidence of IBD is still only below 10% from colonoscopy patients.

Most of them are UC. Female was a most gender see more for both UC and CD. There are significant differences for average age between UC and CD. Key Word(s): 1. Colonoscopy; 2. inflammatory bowel disease Presenting Author: TADAKAZU HISAMATSU Additional Authors: JUN MIYOSHI, KATSUYOSHI MATSUOKA, MAKOTO NAGANUMA, KIYOTO MORI, HIROKI KIYOHARA, KOSAKU NANKI, TOMOHARU YAJIMA, YASUSHI IWAO, HARUHIKO OGATA, TOSHIFUMI HIBI, TAKANORI KANAI Corresponding Author: TADAKAZU HISAMATSU Affiliations: Tokyo Dental College Ichikawa General Hospital, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Keio University School of Medicine, Kitasato University Kitasato Institute Hospital, Keio University School of Medicine Objective: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn’s disease (CD) and analyzed predictive factors for induction and maintenance of clinical remission. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and October 2013. Clinical remission was defined as a Harvey-Bradshaw index of ≤4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week-4.